<DOC>
	<DOCNO>NCT02791516</DOCNO>
	<brief_summary>A multicenter , randomize , double-blind , placebo-controlled study evaluate effect 6 month treatment Romosozumab compare placebo determine percent change bone mineral density</brief_summary>
	<brief_title>A Safety Efficacy Study Evaluate AMG 785 South Korean Women With Osteoporosis .</brief_title>
	<detailed_description>This Phase 3 , multicenter , randomize , double-blind , placebo-controlled study woman osteoporosis . The study design evaluate treatment Romosozumab ( AMG 785 ) month 6 month compare placebo effective increase bone mineral density .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<criteria>Ambulatory postmenopausal Korean woman , ≥ 55 ≤ 90 year age enrollment . Postmenopause define spontaneous vaginal bleeding spot 12 consecutive month prior screen . BMD Tscore &lt; /= 2.50 lumbar spine , total hip femoral neck . At least 2 vertebrae L1 L4 region least one hip evaluable DXA . Other inclusion criterion may apply . Subjects BMD Tscore &lt; /= 4.0 lumbar spine , total hip , femoral neck . History hip fracture . Bone disease osteoporosis/ evidence clinically significant disorder , condition/ disease significant laboratory abnormality . Known sensitivity intolerance calcium vitamin D product . Other exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Osteoporosis .</keyword>
	<keyword>Osteoporosis-Postmenopausal .</keyword>
	<keyword>Bone Diseases-Metabolic .</keyword>
	<keyword>Bone Diseases .</keyword>
	<keyword>Musculoskeletal Diseases .</keyword>
</DOC>